Redwood Pharma will be attending BIO-Europe 2018 in Copenhagen, Nov. 5 – 7 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company’s therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform.
RP101 is the Company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective in two Phase II clinical trials conducted in the US. The active substance is being repurposed and has been formulated in IntelliGel to control its release, reduce dosing and increase compliance. Redwood Pharma will initiate a clinical Phase II trial of RP101 in Europe. Dry eye disease is a large market with serious unmet needs – estimated to grow to USD 2.7 billion in 2022. RP101 will be the first therapy targeted towards a unique biological mechanism and the target patient population of postmenopausal women.
IntelliGel is Redwood Pharma’s exclusive technology for the topical delivery of drugs to the front of the eye using a novel hydrogel based on poloxamers and water. IntelliGel is applied as an eye drop and gels upon contact with the eye. This transparent, lubricating, reversible thermogel allows for better compliance with fewer doses of medicines since the gel keeps the active substance in the eye longer; it allows for a reduction in the amount of active substance administered, a lowering of the number of doses and possible side-effects related to active substance. IntelliGel is currently used in dermatological products commercially sold in the US and China. IntelliGel can be used for both prescription-based, as well as, OTC products.
To schedule a meeting, please do so via BIO-Europe’s online partnering platform at: www.partneringone.com, or contact:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on Spotlight Stock Market, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com